Andrew Hendifar, MD

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Andrew Hendifar, MD sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 3 completed early-phase tilt upper quartile by trial count

Andrew Hendifar, MD: 5 sponsored US clinical trials, none currently recruiting.

Andrew Hendifar, MD sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Pancreas Cancer, with 1 trials.

Upper-quartile sponsor footprint

Andrew Hendifar, MD sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

ACTIVE NOT RECRUITING Early Phase 1

A Feasibility Study of Ketorolac Treatment for Cachexia in Patients With Advanced Pancreatic Ductal Adenocarcinoma

NCT05336266
ACTIVE NOT RECRUITING Phase 2

Pancreaze (Pancrelipase) for Patients With Pancreatic Adenocarcinoma With Cachexia and Exocrine Pancreatic Insufficiency

NCT04098237
COMPLETED Phase 2

Safety and Efficacy of Telatinib in Combination With Keytruda in Subjects With Advanced Stomach and Gastroesophageal Junction Cancers or Hepatocellular Carcinoma

NCT04798781
COMPLETED Phase 1

Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia

NCT03207724
COMPLETED

Evaluating Weight Stability of Pancreatic Cancer Cachexia Patients

NCT02400398

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 2

Therapeutic Areas

Pancreas Cancer 1
Pancreatic Ductal Adenocarcinoma 1
Pancreatic Adenocarcinoma 1
Pancreatic Cancer 1

How the Andrew Hendifar, MD early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).

Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Pancreas Cancer (1 trial), 3 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Andrew Hendifar, MD: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Andrew Hendifar, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Andrew Hendifar, MD4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Andrew Hendifar, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Andrew Hendifar, MD sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Andrew Hendifar, MD page

5 registered trials is a research-attention snapshot, not an endorsement of Andrew Hendifar, MD or any single study.

  • None of Andrew Hendifar, MD's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Pancreas Cancer is the condition Andrew Hendifar, MD studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Pancreas Cancer trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Andrew Hendifar, MD pipeline card: 5 registered trials from official public datasets.Report a data error.